Group 1 - Samsung officially launched its first tri-fold smartphone, Galaxy Z TriFold, on December 2, with a starting price of approximately 17,302 RMB [2][3] - The device features an inward folding design and includes various screen prompts and vibration functions to alert users if the device is folded incorrectly [2] - Notable tech entrepreneur Luo Yonghao criticized the device on social media, questioning its practicality and thickness compared to existing models [2] Group 2 - Xiaomi reported that it has delivered over 500,000 cars since April 3, 2024, exceeding its annual delivery target of 350,000 units for 2025 [5] - The six major banks in China have stopped offering five-year large-denomination certificates of deposit, indicating a trend towards shorter-term products [4] - Canon announced the cessation of operations at its Zhongshan office equipment factory due to a shrinking market for laser printers [8] Group 3 - Michael Burry has shorted Tesla, citing its "absurd" valuation and concerns over a proposed $1 trillion compensation plan for CEO Elon Musk, which could dilute shareholder equity by approximately 3.6% annually [11] - Samsung's semiconductor division has refused to sign long-term contracts for storage chips with its mobile division, opting for quarterly agreements instead [12] - Nvidia's CFO stated that the company has not yet finalized an agreement with OpenAI, despite significant projected orders for AI chips [26]

Core Viewpoint - Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received a drug registration certificate for the innovative drug Anladiwei tablets (brand name: Anruiwei®) from the Macao SAR government, indicating a significant advancement in flu treatment options [1] Group 1 - Anladiwei tablets have shown superior results in a Phase III clinical trial against oseltamivir capsules and placebo, with significant improvements in key endpoints such as time to alleviation of flu symptoms (TTAS) and other viral indicators [1] - The median TTAS and fever relief time for Anladiwei tablets were nearly 10% shorter compared to the oseltamivir group, demonstrating its efficacy [1] - Anladiwei tablets maintain strong inhibitory effects against oseltamivir and mabosavir-resistant viral strains, providing a better treatment option for patients and addressing the issue of antiviral resistance [1] Group 2 - The approval for Anladiwei tablets to be sold in Macao is expected to benefit more flu patients, offering safe and effective treatment choices for physicians and patients alike [1]